-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $114

Benzinga·11/10/2025 20:36:24
Listen to the news
Canaccord Genuity analyst Whitney Ijem maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $105 to $114.